BR112015003785A2 - vírus, vacina, teste de diagnóstico para distinguir mamíferos vacinados com uma vacina, e, uso de um teste de diagnóstico - Google Patents

vírus, vacina, teste de diagnóstico para distinguir mamíferos vacinados com uma vacina, e, uso de um teste de diagnóstico

Info

Publication number
BR112015003785A2
BR112015003785A2 BR112015003785A BR112015003785A BR112015003785A2 BR 112015003785 A2 BR112015003785 A2 BR 112015003785A2 BR 112015003785 A BR112015003785 A BR 112015003785A BR 112015003785 A BR112015003785 A BR 112015003785A BR 112015003785 A2 BR112015003785 A2 BR 112015003785A2
Authority
BR
Brazil
Prior art keywords
vaccine
diagnostic test
virus
vaccinated
csfv
Prior art date
Application number
BR112015003785A
Other languages
English (en)
Inventor
Lamp Benjamin
Wentz Eveline
De Smit Hans
Tilmann Ruemenapf Hans
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112015003785A2 publication Critical patent/BR112015003785A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/9506—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from viruses
    • G01N2333/9513—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from viruses derived from RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

1 / 1 resumo “vãrus, vacina, teste de diagnã“stico para distinguir mamãferos vacinados com uma vacina, e, uso de um teste de diagnã“stico” a presente invenã§ã£o refere-se ao vã­rus da diarrã©ia viral bovina, (bvdv), vã­rus da peste suã­na clã¡ssica (csfv), vã­rus da doenã§a das fronteiras dos ovinos (bdv), e pestivã­rus atã­picos competentes para replicaã§ã£o tendo uma modificaã§ã£o em um epã­topo de uma proteã­na viral, ao seu uso como um medicamento, ao seu uso como uma vacina, ã s vacinas compreendendo tais bvdv, csfv, pestivã­rus atã­picos ou bdv competentes para replicaã§ã£o e aos testes de diagnã³stico para a detecã§ã£o de anticorpos contra tais vã­rus e para distinguir animais vacinados de animais infectados nos campos.
BR112015003785A 2012-08-29 2013-08-28 vírus, vacina, teste de diagnóstico para distinguir mamíferos vacinados com uma vacina, e, uso de um teste de diagnóstico BR112015003785A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12182260 2012-08-29
PCT/EP2013/067771 WO2014033149A1 (en) 2012-08-29 2013-08-28 Marker vaccine

Publications (1)

Publication Number Publication Date
BR112015003785A2 true BR112015003785A2 (pt) 2017-08-08

Family

ID=46785273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003785A BR112015003785A2 (pt) 2012-08-29 2013-08-28 vírus, vacina, teste de diagnóstico para distinguir mamíferos vacinados com uma vacina, e, uso de um teste de diagnóstico

Country Status (11)

Country Link
US (1) US20150290314A1 (pt)
EP (1) EP2890707A1 (pt)
JP (1) JP2015533478A (pt)
CN (1) CN104619720A (pt)
AU (1) AU2013307310A1 (pt)
BR (1) BR112015003785A2 (pt)
MX (1) MX2015002688A (pt)
NZ (1) NZ631110A (pt)
RU (1) RU2015111179A (pt)
WO (1) WO2014033149A1 (pt)
ZA (1) ZA201500656B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104248761B (zh) * 2014-06-24 2018-02-02 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN105717293B (zh) * 2014-12-03 2017-11-10 洛阳普莱柯万泰生物技术有限公司 一种用于检测猪圆环病毒2型的试剂盒
EA038831B1 (ru) * 2015-03-05 2021-10-26 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
AU2016382839A1 (en) * 2015-12-30 2018-06-21 Intervet International B.V. Pestivirus marker vaccine
CN111575404B (zh) * 2020-05-08 2023-03-14 中国兽医药品监察所 对猪瘟野毒及其疫苗、非洲猪瘟病毒进行鉴别诊断的基因芯片以及检测方法
CN111830257B (zh) * 2020-07-17 2023-10-24 南京农业大学 一种猪源胞内劳森菌ipma抗原检测方法及其应用
CN112481220B (zh) * 2020-11-03 2021-09-14 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒解旋酶d1133l单克隆抗体、分泌该单克隆抗体的杂交瘤细胞株及应用
WO2023032008A1 (ja) * 2021-08-30 2023-03-09 日環科学株式会社 免疫賦活化製剤と当該免疫賦活製剤を含有する化粧品、食品、飼料添加物、医薬部外品
CN115975052B (zh) * 2022-12-01 2023-06-27 北京标驰泽惠生物科技有限公司 一种猪瘟病毒的融合蛋白及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567668A (en) * 2005-12-07 2011-07-29 Pfizer Prod Inc Marked bovine viral diarrhea virus vaccines
EP2881468B1 (en) * 2006-04-21 2017-04-12 Intervet International B.V. Pestivirus species
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2010031783A1 (en) * 2008-09-17 2010-03-25 Intervet International B.V. Mutant pestivirus with mutations in core gene and ns3 region

Also Published As

Publication number Publication date
CN104619720A (zh) 2015-05-13
JP2015533478A (ja) 2015-11-26
AU2013307310A1 (en) 2015-02-12
NZ631110A (en) 2015-11-27
RU2015111179A (ru) 2016-10-20
WO2014033149A1 (en) 2014-03-06
ZA201500656B (en) 2017-09-27
US20150290314A1 (en) 2015-10-15
MX2015002688A (es) 2015-05-12
EP2890707A1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
BR112015003785A2 (pt) vírus, vacina, teste de diagnóstico para distinguir mamíferos vacinados com uma vacina, e, uso de um teste de diagnóstico
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
CO2018009434A2 (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue
Artiaga et al. α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
BR112015023507A2 (pt) vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida
BRPI0923599A2 (pt) vírus da febre suína clássica recombinante, vacina para febre suína clássica viva, métodos para proteger um animal contra a febre suína clássica, para diferenciar animais infectados com o vírus da febre suína clássica de animais não infectados ou de animais vacinados com a vacina para febre suína clássica, e para isolar um vírus da febre suína clássica recombinante infeccioso, molécula de cdna, uso do vírus da febre suína clássica recombinante infeccioso, e, elisa com base em peptídeo
BR112018075513A2 (pt) ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
BR112015021341A2 (pt) anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos
BR112016014010A2 (pt) métodos para detectar anticorpos contra vírus da febre suína clássica tipo selvagem (csfv), para diferenciação entre animais infectados com csfv tipo selvagem e animais que foram vacinados contra csfv e para controlar uma infecção com csfv tipo selvagem, kit de teste de diagnóstico, e, uso de um carreador
Owoade et al. Serologic evidence of chicken infectious anemia in commercial chicken flocks in southwest Nigeria
Mohamed et al. A serological survey of Crimean-Congo haemorrhagic fever in animals in the Sharkia Governorate of Egypt
Dräger et al. Efficacy of Suvaxyn CSF Marker (CP7_E2alf) in the presence of pre-existing antibodies against Bovine viral diarrhea virus type 1
Pomorska‐Mól et al. Analysis of the acute‐phase protein response in pigs to clinical and subclinical infection with H 3 N 2 swine influenza virus
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
AR087654A1 (es) METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO
BR112019008720A2 (pt) polinucleotídeo isolado, polinucleotídeo de cdna, polinucleotídeo infeccioso, composição, composição farmacêutica, vetor de pestivírus porcino, pestivírus quimérico, vacina para animais, kit, métodos para proteger um leitão contra uma doença associada com pestivírus, detectar pestivírus, detectar antígeno de pestivírus, preparar uma vacina e controlar uma infecção com um pestivírus em animais, e, ensaio diagnóstico
Toffan et al. Conventional inactivated bivalent H5/H7 vaccine prevents viral localization in muscles of turkeys infected experimentally with low pathogenic avian influenza and highly pathogenic avian influenza H7N1 isolates
BR112016016917A2 (pt) Sistema de administração de fármaco
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
Terregino et al. Conventional H5N9 vaccine suppresses shedding in specific-pathogen-free birds challenged with HPAI H5N1 A/chicken/Yamaguchi/7/2004
Schirrmeier et al. Border disease virus infection in cattle-epidemiological and diagnostic impact
BRPI0920607A2 (pt) composição imunogênica, composição famacêutica, uso de uma ou mais proteínas de s. uberis ancoradas à sortase na preparação de um medicamento, e, métodos para proteger um animal humano ou não dos efeitos de infecção pela s. uberis, e para aumentar uma resposta imune em um animal humano ou não humano.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.